The Genome Analysis Core (GAC or the Core) provides services, advice, and instrumentation for genotyping, gene expression, and epigenetic (methylation) analysis. Using two main platforms, the Sequenom MassArray and the AB 7900HT Real-Time QPCR instrument, the Core provides a variety of services at the low- to medium-throughput level important for understanding the genetics of cancer. Genotyping and mutation analyses of single nucleotide polymorphisms (SNPs) using the Sequenom MassArray are instrumental in helping scientists determine causative mutations in the germline or somatic genes, which lead to certain cancers or human diseases. Methylation analyses provided by the Sequenom MassArray assist in understanding the control of gene expression in tumor progression. A major focus of the Core's services is the use of quantitative real-time PCR (QPCR) on the 7900HT platform. Using a repository of TaqMan assays, the Core provides services for DNA copy number measurements, mRNA and miRNA expression analyses, plus training courses for members of the Helen Diller Family Comprehensive Cancer Center (Center) to learn QPCR techniques. Besides full-service options, most instrumentation is available for independent use by investigators The Center GAC works to improve access by Center members to genetic and genomic technologies. The services we offer, or propose to develop, are actively coordinated with the other UCSF genomics core facilities to avoid detrimental duplication of capacity. For example. Center members have access to extensive high throughput gene expression, genotyping, and sequencing technologies (Affymetrix and Illumina) through Core facilities at UCSF's Parnassus and Mission Bay campuses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA082103-14
Application #
8388373
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-08-05
Project End
2017-05-31
Budget Start
2012-09-19
Budget End
2013-05-31
Support Year
14
Fiscal Year
2012
Total Cost
$324,843
Indirect Cost
$117,386
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Autry, Adam; Phillips, Joanna J; Maleschlijski, Stojan et al. (2017) Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. Transl Oncol 10:895-903
Pekmezci, Melike; Rice, Terri; Molinaro, Annette M et al. (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001-1016
Maertens, Ophélia; McCurrach, Mila E; Braun, Benjamin S et al. (2017) A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res 77:5706-5711
de Smith, Adam J; Kaur, Maneet; Gonseth, Semira et al. (2017) Correlates of Prenatal and Early-Life Tobacco Smoke Exposure and Frequency of Common Gene Deletions in Childhood Acute Lymphoblastic Leukemia. Cancer Res 77:1674-1683
Stieglitz, Elliot; Mazor, Tali; Olshen, Adam B et al. (2017) Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun 8:2127
Bartlett, Thomas E; Müller, Sören; Diaz, Aaron (2017) Single-cell Co-expression Subnetwork Analysis. Sci Rep 7:15066
Martin, Thomas; Baz, Rachid; Benson, Don M et al. (2017) A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood 129:3294-3303
Zhang, Jie; Yao, Tsun-Wen; Hashizume, Rintaro et al. (2017) Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. J Neurooncol 131:495-505
Li, Megan; Kroetz, Deanna L (2017) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther :
Aggarwal, Rahul; Behr, Spencer C; Paris, Pamela L et al. (2017) Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res 15:1221-1229

Showing the most recent 10 out of 168 publications